<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antimycobacterial Drugs | Antimicrobials and Chemotherapy</title>
    
    <!-- Preconnect for performance -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- Main Stylesheet -->
    <link rel="stylesheet" href="../styles/main.css">
    
    <!-- MathJax Configuration -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <!-- Skip Link -->
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <!-- Reading Progress Bar -->
    <div class="reading-progress-container" aria-hidden="true">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Theme Toggle -->
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="page-wrapper">
        <!-- Floating Mini-TOC -->
        <aside class="floating-toc" id="floating-toc" aria-label="On this page">
            <div class="floating-toc-header">
                <span class="floating-toc-icon">üìë</span>
                <span>On this page</span>
            </div>
            <nav class="floating-toc-nav">
                <ul class="floating-toc-list">
                    <!-- Populated by JS -->
                </ul>
            </nav>
        </aside>

        <div class="container">
            <article class="document-article" role="main" id="main-content">
                <!-- Top Navigation -->
                <nav class="document-nav" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">Contents</span>
                        </a>
                        
                        <a href="topic-02-antihelminthics.html" class="nav-button nav-button--prev" aria-label="Previous section">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span class="progress-current">03</span>
                                <span class="progress-separator">/</span>
                                <span class="progress-total">04</span>
                            </div>
                            <div class="progress-bar-container" aria-hidden="true">
                                <div class="progress-bar-fill" style="width: 75%;"></div>
                            </div>
                            <span class="progress-label">Antimycobacterial</span>
                        </div>
                        
                        <a href="topic-04-antiprotozoals.html" class="nav-button nav-button--next" aria-label="Next section">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>

                <!-- Breadcrumb -->
                <nav class="breadcrumb" aria-label="Breadcrumb">
                    <ol class="breadcrumb-list">
                        <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                        <li class="breadcrumb-item active" aria-current="page">Antimycobacterial Drugs</li>
                    </ol>
                </nav>

                <!-- Document Header -->
                <header class="document-header">
                    <div class="header-badge">
                        <span class="badge-icon">üìñ</span>
                        <span class="badge-text">Topic 03</span>
                    </div>
                    <h1 class="document-title">Antimycobacterial Drugs</h1>
                    <div class="title-meta">
                        <span class="meta-item">
                            <span class="meta-icon">üë§</span>
                            <span>Lecturer: mutiso</span>
                        </span>
                        <span class="meta-item">
                            <span class="meta-icon">üìÖ</span>
                            <span>14/12/2025</span>
                        </span>
                    </div>
                </header>

                <!-- Main Content Area -->
                <div class="content-wrapper">
                    
                    <!-- Introduction -->
                    <section id="introduction" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">01</div>
                            <h2 class="section-title">Introduction</h2>
                        </div>
                        <div class="content-card">
                            <p>Mycobacteria are intrinsically resistant to most antibiotics. Reasons include:</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker">1</span>
                                    <span class="list-content">They grow slowly compared with other bacteria- antibiotics that are most active against growing cells are relatively ineffective</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">2</span>
                                    <span class="list-content">Mycobacterial cells can also be dormant and thus completely resistant to many drugs or killed only very slowly</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">3</span>
                                    <span class="list-content">The lipid-rich mycobacterial cell wall is impermeable to many agents</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">4</span>
                                    <span class="list-content">Mycobacterial species are intracellular pathogens, and organisms residing within macrophages are inaccessible to drugs that penetrate these cells poorly</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">5</span>
                                    <span class="list-content">Mycobacteria are notorious for their ability to develop resistance</span>
                                </li>
                            </ol>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Combinations of two or more drugs are required to overcome these obstacles and to prevent emergence of resistance during the course of therapy</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Response of mycobacterial infections to chemotherapy is slow, and treatment must be administered for months</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Classification of Drugs -->
                    <section id="drug-classification" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">02</div>
                            <h2 class="section-title">Drug Classification</h2>
                        </div>
                        <div class="content-card">
                            <p>They are classified into 1st line and 2nd line therapy. First-line agents are superior in efficacy and possess an acceptable degree of toxicity.</p>
                            
                            <h3 class="section-title">1st line therapy</h3>
                            <p>Isoniazid and rifampin are the two most active drugs.</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Isoniazid (INH)</strong></span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Rifampin (or other rifamycin)</strong></span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Pyrazinamide</strong></span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Ethambutol</strong></span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Streptomycin</strong></span>
                                </li>
                            </ul>

                            <h3 class="section-title">2nd line therapy</h3>
                            <p>They are more toxic and less effective. Are usually considered only In case of:</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker">1</span>
                                    <span class="list-content">Resistance to first-line agents</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">2</span>
                                    <span class="list-content">Failure of clinical response to conventional therapy</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">3</span>
                                    <span class="list-content">Serious treatment-limiting adverse drug reactions</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">4</span>
                                    <span class="list-content">When expert guidance is available to deal with the toxic effects</span>
                                </li>
                            </ol>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Ethionamide</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Capreomycin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Cycloserine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Aminosalicylic Acid (PAS)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Kanamycin & Amikacin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Fluoroquinolones</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Thiacetazone</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rifabutin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rifapentine</span></li>
                            </ul>
                        </div>
                    </section>

                    <!-- Treatment Regimens -->
                    <section id="regimens" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">03</div>
                            <h2 class="section-title">Standard Treatment Regimen</h2>
                        </div>
                        <div class="content-card">
                            <p>In practice, therapy is initiated with a four-drug regimen of isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin.</p>
                            
                            <h3 class="section-title">Initial Phase (Intensive Phase)</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>2RHZE</strong> or <strong>2RHZE</strong> + <strong>S</strong> (Streptomycin)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Daily treatment with appropriate patient support for <strong>two months</strong> with: Streptomycin (S) + Ethambutol (E) + Rifampicin (R) + Isoniazid (H) + Pyrazinamide (Z)</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Continuation Phase</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>4RH</strong> or <strong>4RHE</strong></span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Daily treatment with appropriate patient support for <strong>five months</strong> with Ethambutol (E) + Rifampicin (R) + Isoniazid (H)</span>
                                </li>
                            </ul>

                            <aside class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <span class="callout-title">Regimen Abbreviation</span>
                                </div>
                                <div class="callout-content">
                                    <p>The whole regime is often abbreviated as: <strong>2SRHZE/1RHZE/5RHE</strong> (For both Intensive and continuation phases in retreatment scenarios).</p>
                                </div>
                            </aside>
                        </div>
                    </section>

                    <!-- Pregnancy -->
                    <section id="pregnancy" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">04</div>
                            <h2 class="section-title">Treatment of TB in Pregnancy</h2>
                        </div>
                        <div class="content-card">
                            <p>Like most drugs anti-TB drugs have not been specifically studied in pregnancy. There is always some risk of teratogenicity with any drugs especially when the drug is given in the first trimester. In general, pregnancy should be avoided during anti TB treatment.</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">TB should be treated with a full complement of anti-TB drugs</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Useful to give <strong>Pyridoxine with Isoniazid</strong> to avoid the small risk of damaging the infant's nervous system</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Streptomycin should not be used</strong> in pregnancy because it may cause deafness in the infant</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Aminoglycosides used in treatment of drug resistant TB like: Kanamycin, Amikacin and Capreomycin and the thioamides: Ethionamide and Prothionamide should not be used in pregnancy because of associated ototoxity</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Drug Resistant TB -->
                    <section id="drug-resistant-tb" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">05</div>
                            <h2 class="section-title">Drug Resistant TB</h2>
                        </div>
                        <div class="content-card">
                            <h3 class="section-title">Classification based on exposure</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Primary resistance</strong>- if there was definitely no previous treatment.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Initial resistance</strong>-when previous treatment cannot definitely be excluded.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Acquired resistance</strong>-if there is a definite history of previous treatment</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Based on the type of resistance expressed by the TB bacilli</h3>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker">1</span>
                                    <span class="list-content"><strong>Mono-resistant TB</strong>- TB which is resistant to one first line anti -TB Drug.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">2</span>
                                    <span class="list-content"><strong>Poly resistant TB</strong>- TB which is resistant to more than one anti-TB drug except both Rifampicin and Isoniazid.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">3</span>
                                    <span class="list-content"><strong>Multi-Drug Resistant (MDR) TB</strong>- resistance to both Rifampicin and Isoniazid</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">4</span>
                                    <span class="list-content"><strong>Extensively drug Resistant (XDR) TB</strong>- is MDR-TB (i.e further to being resistant to Rifampicin and Isoniazid) it is also resistant to any fluoroquinolone and one or more of the following injectable drugs: Kanamycin, Amikacin and Capreomycin</span>
                                </li>
                            </ol>
                        </div>
                    </section>

                    <!-- Therapy for Resistant TB -->
                    <section id="therapy-resistant-tb" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">06</div>
                            <h2 class="section-title">Drug Therapy of Resistant TB</h2>
                        </div>
                        <div class="content-card">
                            <h3 class="section-title">Mono-resistant TB</h3>
                            <p>When there is resistance to any one only one first line antituberculosis drug. Only the offending drug should be substituted:</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Ethambutol replaces Isoniazid</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Fluoroquinolone replaces Rifampicin</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Poly-resistant TB</h3>
                            <p>When there is resistance to two or more first line anti TB drugs other than both Rifampicin and Isoniazid. The two offending drugs should be replaced.</p>

                            <h3 class="section-title">MDR TB</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">This is mycobacteria that is resistant to both Isoniazid and Rifampicin</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Treatment is in two phases: Intensive phase lasts 6 months; Continuation phase lasts for 18 months</span>
                                </li>
                            </ul>

                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üíä</span>
                                    <span class="table-caption">Drugs used for MDR TB</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table">
                                        <thead>
                                            <tr>
                                                <th>Category</th>
                                                <th>Drugs</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td><strong>First line oral anti TB</strong></td>
                                                <td>1.Pyrazinamide(Z)<br>2.Ethambutol(E)<br>3.Rifampicin(R)<br>4.Isoniazid(H)</td>
                                            </tr>
                                            <tr>
                                                <td><strong>Injectable anti- TB agent</strong></td>
                                                <td>1.Streptomycin (S)<br>2.Kanamycin (Km)<br>3.Amikacin (Am)<br>4.Capreomycin (Cm)<br>5.Viomycin (Vi)</td>
                                            </tr>
                                            <tr>
                                                <td><strong>Second line fluoroquinolones</strong></td>
                                                <td>1. Ciprofloxacin (Cfx)<br>2.Ofloxacin (Ofx)<br>3.Levofloxacin (Lfx)<br>4.Moxifloxacin (Mfx)<br>5.Gatifloxacin (Gfx)<br>6.Sparfloxacin</td>
                                            </tr>
                                            <tr>
                                                <td><strong>Oral bacteriostatic second-line</strong></td>
                                                <td>1.Ethionamide (Eto)<br>2.Protionamide (Pto)<br>3.Cycloserine (Cs)<br>4.Terizidone (Trd)<br>5.P-amino salicylic acid (PAS)<br>6.Thioacetazone (Th)</td>
                                            </tr>
                                            <tr>
                                                <td><strong>Third line anti-TB agents</strong></td>
                                                <td>1.Clofazimine (Cfz)<br>2.Amoxicillin/Clavulanate (Amx/Clv)<br>3.Clarithromycin (Clr)</td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <h4 class="section-title">Standard MDR Regimen</h4>
                            <p><strong>6 Km-Pto-Lfx-Cs-(E/Z) / 18 Pto-Lfx-Cs-(E/Z)</strong></p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker">1</span>
                                    <span class="list-content"><strong>6 months of:</strong> Kanamycin (injectable), Protionamide, Levofloxacin, Cycloserine & either Ethambutol <strong>or</strong> Pyrazinamide</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">2</span>
                                    <span class="list-content"><strong>plus 18 months of:</strong> Protionamide, Levofloxacin, Cycloserine & either Ethambutol <strong>or</strong> Pyrazinamide</span>
                                </li>
                            </ol>
                        </div>
                    </section>

                    <!-- RIFAMPIN -->
                    <section id="rifampin" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">07</div>
                            <h2 class="section-title">RIFAMPIN</h2>
                        </div>
                        <div class="content-card">
                            <p><strong>MOA:</strong> Binds to the beta subunit of bacterial DNA-dependent RNA polymerase and thereby inhibits RNA synthesis.</p>
                            
                            <h3 class="section-title">PK</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Well absorbed after oral administration</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Excreted mainly through the liver into bile</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Undergoes enterohepatic circulation</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Bulk is excreted as a deacylated metabolite in feces and a small amount in the urine</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Dosage adjustment for renal or hepatic insufficiency is not necessary.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Distributed widely in body fluids and tissues. Relatively highly protein-bound.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Adequate CSF concentrations achieved only in the presence of meningeal inflammation</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Clinical uses</h3>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker">1</span>
                                    <span class="list-content">Mycobacterial infections: rifampin, $600 \mathrm{mg} / \mathrm{d}(10 \mathrm{mg} / \mathrm{kg} / \mathrm{d})$ orally, coadministered with isoniazid to avoid emergence of resistance</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">2</span>
                                    <span class="list-content">An oral dosage of 600 mg twice daily for 2 days can eliminate meningococcal carriage</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">3</span>
                                    <span class="list-content">$20 \mathrm{mg} / \mathrm{kg} / \mathrm{d}$ for 4 days, is used as prophylaxis in contacts of children with Haemophilus influenzae</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">4</span>
                                    <span class="list-content">Combined with a second agent it is used to eradicate staphylococcal carriage</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker">5</span>
                                    <span class="list-content">Rifampin combination therapy is also indicated for treatment of serious staphylococcal infections such as osteomyelitis and prosthetic valve endocarditis</span>
                                </li>
                            </ol>

                            <h3 class="section-title">ADR</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Imparts a harmless orange color to urine, sweat, tears, and contact lenses (soft lenses may be permanently stained)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Occasional may cause rashes, thrombocytopenia, and nephritis</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">May also cause cholestatic jaundice and occasionally hepatitis</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Commonly causes light-chain proteinuria</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">If administered less often than twice weekly, it causes a flu-like syndrome characterized by fever, chills, myalgias, anemia, and thrombocytopenia and sometimes is associated with acute tubular necrosis</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Drug interaction</h3>
                            <p>Induces most cytochrome P450 isoforms hence increases the elimination of other drugs including: methadone, anticoagulants, cyclosporine, some anticonvulsants, protease inhibitors, Non-nucleoside reverse transcriptase inhibitors etc. Administration of rifampin results in significantly lower serum levels of these drugs</p>
                        </div>
                    </section>

                    <!-- ISONIAZID -->
                    <section id="isoniazid" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">08</div>
                            <h2 class="section-title">ISONIAZID</h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">A synthetic agent with a structural similarity to that of pyridoxine</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>MOA:</strong> Inhibits synthesis of mycolic acids (fatty acids), which are essential components of mycobacterial cell walls</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Resistance:</strong> Is associated with mutations</span>
                                </li>
                            </ul>

                            <!-- Figure -->
                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/img-1.jpeg" 
                                         alt="PK details of Isoniazid including absorption and distribution" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Pharmacokinetics of Isoniazid.</figcaption>
                            </figure>

                            <h3 class="section-title">PK</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Readily absorbed from the gastrointestinal tract</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">A 300-mg oral dose (5 mg/kg in children) achieves peak plasma concentrations of 3-5 mcg/mL within 1-2 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It diffuses readily into all body fluids and tissues</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Metabolism</strong>: Is by acetylation by liver <em>N</em>-acetyltransferase and is genetically determined; some individuals are slow acetylators while others are rapid acetylators</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Metabolites and a small amount of unchanged drug are excreted mainly in the urine</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Adverse Reactions</h3>
                            <p>The incidence and severity ADRs are related to dosage and duration of Rx.</p>
                            <h4 class="section-title">A. IMMUNOLOGIC REACTIONS</h4>
                            <p>Fever and skin rashes; Drug-induced systemic lupus erythematosus</p>
                            <h4 class="section-title">B. DIRECT TOXICITY</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Isoniazid-induced hepatitis</strong>- risk increase with age, is rare in patients below 20 yrs. Clinical hepatitis with loss of appetite, nausea, vomiting, jaundice, and right upper quadrant pain occurs. Risk of hepatitis is greater in alcoholics, during pregnancy and the postpartum period.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Peripheral neuropathy</strong> -observed in 10-20% of patients- occur more in slow acetylators and patients with predisposing conditions. Occur due to a relative pyridoxine deficiency. Isoniazid promotes excretion of pyridoxine.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Central nervous system toxicity: memory loss, psychosis, and seizures.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hematologic abnormalities, provocation of pyridoxine deficiency anemia, Tinnitus, Gastrointestinal discomfort.</span>
                                </li>
                            </ul>
                            
                            <h3 class="section-title">Drug interaction</h3>
                            <p>Isoniazid can reduce the metabolism of phenytoin, increasing its blood level and toxicity</p>
                        </div>
                    </section>

                    <!-- ETHAMBUTOL -->
                    <section id="ethambutol" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">09</div>
                            <h2 class="section-title">ETHAMBUTOL</h2>
                        </div>
                        <div class="content-card">
                            <p><strong>MOA:</strong> Inhibits mycobacterial arabinosyl transferases an enzyme involved in the polymerization reaction of arabinoglycan, an essential component of the mycobacterial cell wall.</p>
                            
                            <h3 class="section-title">PK</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Well absorbed from the gut; blood level peak is reached in 2-4 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Excretion: About 20% excreted in feces and $50 \%$ in urine in unchanged form</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The drug accumulates in renal failure and dose should be reduced by half if creatinine clearance is less than 10 $\mathrm{mL} / \mathrm{min}$</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Ethambutol crosses the blood-brain barrier only if the meninges are inflamed</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Clinical uses</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Usually given as a single daily dose in combination with isoniazid or rifampin</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">A higher dose is recommended for treatment of tuberculous meningitis</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Adverse Reactions</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hypersensitivity to ethambutol is rare</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Most common serious ADR is <strong>optic neuritis</strong>- result in loss of visual acuity and red-green color blindness- a doserelated side effect (More likely to occur at doses of 25 $\mathrm{mg} / \mathrm{kg} / \mathrm{d}$ continued for several months)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Periodic visual acuity testing is desirable if the 25 mg/kg/d dosage is used</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Relatively contraindicated in children too young to permit assessment of visual acuity and red-green color discrimination</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- PYRAZINAMIDE -->
                    <section id="pyrazinamide" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">10</div>
                            <h2 class="section-title">PYRAZINAMIDE</h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Stable, and slightly soluble in water. Inactive at neutral pH, Inhibits tubercle bacilli and some other mycobacteria at pH 5.5</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The drug is taken up by macrophages and exerts its activity against mycobacteria residing within the acidic environment of lysosomes</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It is converted to pyrazinoic acid the active form of the drug by mycobacterial pyrazinamidase</span>
                                </li>
                            </ul>

                            <h3 class="section-title">PK</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Well absorbed from the gastrointestinal tract</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Widely distributed in body tissues, including inflamed meninges</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The half-life is 8-11 hours</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The parent compound is metabolized by the liver, metabolites are renally cleared</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Adverse Reactions</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hepatotoxicity</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Nausea, Vomiting, Drug fever</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hyperuricemia -may provoke acute gouty arthritis</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- STREPTOMYCIN -->
                    <section id="streptomycin" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">11</div>
                            <h2 class="section-title">STREPTOMYCIN</h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">An aminoglycoside</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Penetrates into cells poorly and is active mainly against extracellular tubercle bacilli</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Streptomycin crosses the blood-brain barrier and achieves therapeutic concentrations with inflamed meninges</span>
                                </li>
                            </ul>

                            <h3 class="section-title">Clinical use</h3>
                            <p>Used when an injectable drug is needed or desirable, principally in individuals with severe, possibly life-threatening forms of tuberculosis, e.g. meningitis and disseminated disease, and in treatment of infections resistant to other drugs</p>
                        </div>
                    </section>

                    <!-- Retreatment -->
                    <section id="retreatment" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">12</div>
                            <h2 class="section-title">Retreatment</h2>
                        </div>
                        <div class="content-card">
                            <p>For patients who have previously been treated for TB for more than one month including those who:</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Have relapsed after successful previous treatment, or</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Those who defaulted from previous treatment or</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Failed previous treatment, with sputum smears remaining positive at 4/5, 6/8 month</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                </div>

                <!-- Bottom Navigation -->
                <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="topic-02-antihelminthics.html" class="nav-button nav-button--prev nav-button--large">
                            <span class="nav-icon">‚Üê</span>
                            <div class="nav-content">
                                <span class="nav-label">Previous</span>
                                <span class="nav-title">Antihelminthics</span>
                            </div>
                        </a>
                        
                        <a href="../index.html" class="nav-button nav-button--toc">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">All Topics</span>
                        </a>
                        
                        <a href="topic-04-antiprotozoals.html" class="nav-button nav-button--next nav-button--large">
                            <div class="nav-content">
                                <span class="nav-label">Next</span>
                                <span class="nav-title">Antiprotozoals</span>
                            </div>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>